Okomera Signs First Commercial Platform Deal With Servier

PARIS, France — October 21, 2026

Okomera Platform Supports Tumor Response Analysis

Okomera’s technology is designed to help researchers study how tumors respond to different treatments by using miniaturized models derived from human tumor biology. The platform combines microfluidics, tumor mini-avatars and artificial intelligence-powered imaging to generate standardized spheroid cultures and analyze treatment responses. According to Okomera, the integrated system allows users to manage the workflow independently, from culture generation through data production, within a single machine designed to function as a decentralized laboratory. Under the agreement, Servier’s research teams will use the platform to characterize treatment responses and investigate biological mechanisms that may inform the development of new therapies. The approach addresses a major challenge in oncology drug development: identifying promising therapeutic candidates early enough to improve research efficiency. Okomera cited the high attrition rate of oncology drug candidates as a key reason for developing technologies that can provide measurable evidence of tumor response during preclinical research. However, the announcement did not disclose specific research programs, study timelines or experimental results generated through the collaboration.

Collaboration Targets Pancreatic Cancer and Glioblastoma

Servier plans to apply Okomera’s platform to evaluate new therapeutic approaches in oncology and immuno-oncology, with a particular focus on pancreatic cancer and glioblastoma. Nicolas Molinié, Group Leader Target Discovery at Servier, said the technology enables the generation of standardized data from human tumor models and could help researchers better characterize treatment-response mechanisms and identify promising therapeutic directions more quickly. For Okomera, the agreement represents an expansion from technology development toward commercial deployment within pharmaceutical research laboratories. Silvère Lucquin, Chief Executive Officer of Okomera, said the collaboration reflects several years of research and development and growing adoption of the company’s technology. The agreement also demonstrates a practical application of integrated tumor-modeling technology within an established pharmaceutical research environment. Although the platform is intended to support the selection and evaluation of potential treatment strategies, the announcement did not report evidence that its use has improved clinical outcomes or confirmed the effectiveness of any specific drug candidate.

Okomera Advances Functional Precision Oncology

Founded in 2020 as a spin-off from École Polytechnique and Institut Pasteur, Okomera is developing technology intended to bring functional precision oncology into routine clinical practice. The company uses patient biopsy samples to create miniaturized tumor models and analyze how those models respond to different treatments. Its broader approach spans preclinical research, clinical trials and potential applications in patient care, with the aim of placing biological treatment-response data at the center of therapeutic decision-making. The company says this approach could help clinicians and researchers identify treatment options more effectively, although the current agreement with Servier specifically concerns research and therapeutic development. Servier’s independent operation of the platform will enable its teams to generate standardized experimental data within their own laboratory workflows. The commercial installation marks a step in Okomera’s effort to deploy its technology beyond its own research environment and establish partnerships with pharmaceutical organizations. Further results from the collaboration may help demonstrate how tumor mini-avatars and AI-assisted analysis can contribute to preclinical oncology research.

Source:::Okomera,,,press release